IMMUTEP Ltd
corporate_fare Company Profile
IMMUTEP Ltd (NASDAQ:IMMP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 14 items for IMMP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-11, rated 7/10. Across its 14 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for IMMP spans 6-K.
Recent high-impact activity:
- Immutep Pivots Efti Strategy to HNSCC and STS After TACTI-004 Root Cause Analysis
- Immutep FY26 Annual Report: A$79.3M Loss, Nasdaq Bid Price Deficiency, and Novartis Exit
- Immutep Reports A$68.9M Cash, Extends Runway to H1 2028 After TACTI-004 Wind-Down
- Immutep's Efti Shows 30.9-Month Survival in Lung Cancer, TACTI-004 Analysis Reveals Immune Profile Shift
- Immutep Reports Positive Interim Phase I Data for Autoimmune Candidate IMP761
Financial Snapshot
Insider Transactions
IMMP files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.